Patient details
| Patient no. . | Sex . | Diagnosis . | FBC at diagnosis . | Time to study, y . | FBC at study . | Thrombosis, Y/N . | Treatment . | Response . | Transfusion, Y/N . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hb . | Neut . | Plts . | Hb . | Neut . | Plts . | ||||||||
| 1 | M | SAA | 4.5 | 2.2 | 5.0 | < 0.1 | 4.5 | 2.2 | 5.0 | N | csa, G-CSF | PR | Y (red + plts) |
| 2 | M | nSAA | 8.7 | 2.0 | 21.0 | 6 | 10.4 | 7.3 | 67.0 | Y* | ALG, csa | PR | N |
| 3 | M | SAA | na | na | na | 2 | 11.4 | 0.8 | 23.0 | N | ALG, csa | PR | Y (red + plts) |
| 4 | F | SAA | 9.1 | 0.8 | 17.0 | 9 | 9.1 | 1.0 | 54.0 | N | ATG, csa | PR | N |
| 5 | F | SAA | na | na | na | < 0.1 | na | na | na | N | ALG, csa, G-CSF | PR | Y (red + plts) |
| 6 | M | vSAA | na | na | na | 0.2 | na | na | na | N | ALG, csa, G-CSF | PR | Y (red + plts) |
| 7 | M | vSAA | na | na | na | 0.4 | na | na | na | N | ALG, csa, G-CSF | CR | N |
| 8 | F | SAA | na | na | na | < 0.1 | na | na | na | na | na | na | na |
| 9 | F | SAA | na | na | na | < 0.1 | na | na | na | N | ALG, csa, G-CSF | CR | N |
| 10 | M | SAA | na | na | na | 3 | na | na | na | N | ALG, csa, G-CSF | CR | N |
| 11 | M | SAA | na | na | na | 5 | 10.4 | 4.0 | 159.0 | N | csa | PR | N |
| 12 | F | SAA | na | na | na | < 0.1 | na | na | na | na | na | na | na |
| 13 | F | SAA | na | na | na | 0.2 | na | na | na | na | ALG, csa, G-CSF | na | na |
| 14 | F | SAA | na | na | na | 4 | 11.4 | 3.6 | 84.0 | N | ALG, csa | PR | N |
| 15 | F | vSAA | 7.7 | 0.1 | 10.0 | 3 | 6.2 | 0.4 | 31.0 | N | ALG, csa, G-CSF | CR† | Y (red + plts) |
| 16 | F | nSAA | 10.0 | 1.2 | 20.0 | 0.1 | 11.0 | 1.5 | 90.0 | ?‡ | csa | na | Y (red + plts) |
| 17 | F | nSAA | 8.5 | 0.8 | 28.0 | 0.7 | 7.9 | 4.4 | 47.0 | N | ALG, csa | CR | Y (red + plts) |
| 18 | F | SAA | 8.1 | 1.1 | 6.0 | 0.2 | 6.3 | 0.9 | 10.0 | N | ALG, csa | CR | Y (red + plts) |
| 19 | F | nSAA | 6.9 | 0.6 | 12.0 | 14 | 8.4 | 1.1 | 27.0 | N | Metenolon | CR | Y (red + plts) |
| 20 | M | AA | 9.9 | 0.7 | 28 | 5 | 13.4 | 5.2 | 165 | N | ALGx2, oxy, csa | CR | N |
| 21 | M | AA | 7 | 1 | 15 | 7 | 13 | 2.6 | 56 | N | ALGx2, oxy, csa | PR | N |
| 22 | M | AA | 8 | 0.6 | 13 | 3 | 12.9 | 2.2 | 75 | Y | ALGx2, csa | PR | N |
| 23 | F | AA | 10.5 | 0.9 | 10 | 15 | 10.4 | 0.6 | 39 | N | ALG, oxy | PR | N |
| 24 | M | AA | na | na | na | 10 | 11.9 | 2 | 64 | Y | ALGx2, oxy | N/A | N |
| 25 | M | AA | 11.8 | 1.3 | 36 | 7 | 15.1 | 2.4 | 119 | N | ALGx2, csa | PR | N |
| 26 | M | AA | 6 | < 0.1 | 10 | 1.2 | 7.7 | 6.2 | 26 | N | ALG, GCSF, csa | NR | Y (red + plts) |
| 27 | M | AA | 7.1 | 0.8 | 7 | 3 | 9.1 | 0.2 | 10 | N | ALGx2, oxy, csa | NR | Y (red + plts) |
| 28 | M | AA | 6.1 | 1 | 8 | 2 | 9.5 | 1 | 22 | N | ALGx2, csa | NR | Y (red + plts) |
| 29 | F | AA | 10 | 1.1 | 30 | 4 | 11.4 | 1.8 | 89 | N | Nil | N/A1-153 | N |
| 30 | F | AA | 5.1 | 0.3 | 9 | 26 | 10.7 | 0.5 | 20 | N | pred, oxy | NR | Y(red) |
| 31 | F | AA | 4.5 | 0.5 | 18 | 3 | 8.7 | 3.6 | 197 | N | ALG, csa | PR | Y(red) |
| 32 | M | AA | 6 | 0.4 | 13 | 7 | 13.1 | 2.4 | 125 | N | ALG, oxy | PR | N |
| 33 | F | AA | 8.2 | 2.5 | 50 | 10 | 8.3 | 1.6 | 17 | N | Nil | N/A1-153 | Y(red) |
| 34 | F | AA | na | na | na | 13 | 8.8 | 1 | 95 | N | ALGx2, oxy, csa | PR | Y(red) |
| 35 | M | AA | 5.8 | 0.5 | 14 | 0.2 | 10 | 1.1 | 74 | N | Nil | N/A1-153 | Y(red + plts) |
| 36 | M | AA | 8.7 | na | 40 | 34 | 13 | 2.9 | 115 | N | csa | PR | N |
| 37 | M | AA | na | na | na | 5 | 7.8 | 0.4 | 41 | N | csa | NR | Y(red + plts) |
| 38 | F | AA | 5.7 | 1.1 | 4 | 0.3 | 14 | 6.3 | 15 | N | ALG, G-CSF | NR | Y(red + plts) |
| 39 | M | AA | na | na | na | 2 | 10 | 0.3 | 4 | N | ALG, csa | NR | Y(red + plts) |
| 40 | F | AA | na | na | na | 5 | 11 | 1.7 | 223 | N | ALGx2, csa | R | N |
| Patient no. . | Sex . | Diagnosis . | FBC at diagnosis . | Time to study, y . | FBC at study . | Thrombosis, Y/N . | Treatment . | Response . | Transfusion, Y/N . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hb . | Neut . | Plts . | Hb . | Neut . | Plts . | ||||||||
| 1 | M | SAA | 4.5 | 2.2 | 5.0 | < 0.1 | 4.5 | 2.2 | 5.0 | N | csa, G-CSF | PR | Y (red + plts) |
| 2 | M | nSAA | 8.7 | 2.0 | 21.0 | 6 | 10.4 | 7.3 | 67.0 | Y* | ALG, csa | PR | N |
| 3 | M | SAA | na | na | na | 2 | 11.4 | 0.8 | 23.0 | N | ALG, csa | PR | Y (red + plts) |
| 4 | F | SAA | 9.1 | 0.8 | 17.0 | 9 | 9.1 | 1.0 | 54.0 | N | ATG, csa | PR | N |
| 5 | F | SAA | na | na | na | < 0.1 | na | na | na | N | ALG, csa, G-CSF | PR | Y (red + plts) |
| 6 | M | vSAA | na | na | na | 0.2 | na | na | na | N | ALG, csa, G-CSF | PR | Y (red + plts) |
| 7 | M | vSAA | na | na | na | 0.4 | na | na | na | N | ALG, csa, G-CSF | CR | N |
| 8 | F | SAA | na | na | na | < 0.1 | na | na | na | na | na | na | na |
| 9 | F | SAA | na | na | na | < 0.1 | na | na | na | N | ALG, csa, G-CSF | CR | N |
| 10 | M | SAA | na | na | na | 3 | na | na | na | N | ALG, csa, G-CSF | CR | N |
| 11 | M | SAA | na | na | na | 5 | 10.4 | 4.0 | 159.0 | N | csa | PR | N |
| 12 | F | SAA | na | na | na | < 0.1 | na | na | na | na | na | na | na |
| 13 | F | SAA | na | na | na | 0.2 | na | na | na | na | ALG, csa, G-CSF | na | na |
| 14 | F | SAA | na | na | na | 4 | 11.4 | 3.6 | 84.0 | N | ALG, csa | PR | N |
| 15 | F | vSAA | 7.7 | 0.1 | 10.0 | 3 | 6.2 | 0.4 | 31.0 | N | ALG, csa, G-CSF | CR† | Y (red + plts) |
| 16 | F | nSAA | 10.0 | 1.2 | 20.0 | 0.1 | 11.0 | 1.5 | 90.0 | ?‡ | csa | na | Y (red + plts) |
| 17 | F | nSAA | 8.5 | 0.8 | 28.0 | 0.7 | 7.9 | 4.4 | 47.0 | N | ALG, csa | CR | Y (red + plts) |
| 18 | F | SAA | 8.1 | 1.1 | 6.0 | 0.2 | 6.3 | 0.9 | 10.0 | N | ALG, csa | CR | Y (red + plts) |
| 19 | F | nSAA | 6.9 | 0.6 | 12.0 | 14 | 8.4 | 1.1 | 27.0 | N | Metenolon | CR | Y (red + plts) |
| 20 | M | AA | 9.9 | 0.7 | 28 | 5 | 13.4 | 5.2 | 165 | N | ALGx2, oxy, csa | CR | N |
| 21 | M | AA | 7 | 1 | 15 | 7 | 13 | 2.6 | 56 | N | ALGx2, oxy, csa | PR | N |
| 22 | M | AA | 8 | 0.6 | 13 | 3 | 12.9 | 2.2 | 75 | Y | ALGx2, csa | PR | N |
| 23 | F | AA | 10.5 | 0.9 | 10 | 15 | 10.4 | 0.6 | 39 | N | ALG, oxy | PR | N |
| 24 | M | AA | na | na | na | 10 | 11.9 | 2 | 64 | Y | ALGx2, oxy | N/A | N |
| 25 | M | AA | 11.8 | 1.3 | 36 | 7 | 15.1 | 2.4 | 119 | N | ALGx2, csa | PR | N |
| 26 | M | AA | 6 | < 0.1 | 10 | 1.2 | 7.7 | 6.2 | 26 | N | ALG, GCSF, csa | NR | Y (red + plts) |
| 27 | M | AA | 7.1 | 0.8 | 7 | 3 | 9.1 | 0.2 | 10 | N | ALGx2, oxy, csa | NR | Y (red + plts) |
| 28 | M | AA | 6.1 | 1 | 8 | 2 | 9.5 | 1 | 22 | N | ALGx2, csa | NR | Y (red + plts) |
| 29 | F | AA | 10 | 1.1 | 30 | 4 | 11.4 | 1.8 | 89 | N | Nil | N/A1-153 | N |
| 30 | F | AA | 5.1 | 0.3 | 9 | 26 | 10.7 | 0.5 | 20 | N | pred, oxy | NR | Y(red) |
| 31 | F | AA | 4.5 | 0.5 | 18 | 3 | 8.7 | 3.6 | 197 | N | ALG, csa | PR | Y(red) |
| 32 | M | AA | 6 | 0.4 | 13 | 7 | 13.1 | 2.4 | 125 | N | ALG, oxy | PR | N |
| 33 | F | AA | 8.2 | 2.5 | 50 | 10 | 8.3 | 1.6 | 17 | N | Nil | N/A1-153 | Y(red) |
| 34 | F | AA | na | na | na | 13 | 8.8 | 1 | 95 | N | ALGx2, oxy, csa | PR | Y(red) |
| 35 | M | AA | 5.8 | 0.5 | 14 | 0.2 | 10 | 1.1 | 74 | N | Nil | N/A1-153 | Y(red + plts) |
| 36 | M | AA | 8.7 | na | 40 | 34 | 13 | 2.9 | 115 | N | csa | PR | N |
| 37 | M | AA | na | na | na | 5 | 7.8 | 0.4 | 41 | N | csa | NR | Y(red + plts) |
| 38 | F | AA | 5.7 | 1.1 | 4 | 0.3 | 14 | 6.3 | 15 | N | ALG, G-CSF | NR | Y(red + plts) |
| 39 | M | AA | na | na | na | 2 | 10 | 0.3 | 4 | N | ALG, csa | NR | Y(red + plts) |
| 40 | F | AA | na | na | na | 5 | 11 | 1.7 | 223 | N | ALGx2, csa | R | N |
FBC indicates full blood count; Hb, hemoglogin levels; Neut, neutrophil counts; Plts, platelets; AA, aplastic anemia; SAA, severe AA; csa, cyclosporin; PR, partial response (response defined as per Consensus Conference on Treatment of Aplastic Anaemia); red, red-cell transfusions; nSAA, nonsevere AA; na, not available; vSAA, very severe AA; CR, complete response; oxy, oxymetholone; pred, prednisolone; N/A, not applicable; and NR, no response.
Portal vein thrombosis.
Relapsed at time of study, retreated with ATG, csa, G-CSF and achieved PR.
? Abdominal pain crises, possibly due to mesenterial vessel thrombosis.
Studied before treatment started.